EXEL•benzinga•
Exelixis To Present STELLAR-002 Trial Data At ASCO 2025 Showing Zanzalintinib Plus Nivolumab Achieved 63% Response Rate And 90% Disease Control In Untreated Advanced Clear Cell RCC, Alongside Additional Dose-Finding Results
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2025 by benzinga